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ABSTRACT
Importance Advances in mobile technology
have resulted in federal and industry-level
initiatives to facilitate large-scale clinical research
using smart devices. Although the benefits of
technology to expand data collection are
obvious, assumptions about the reach of mobile
research methods (access), participant willingness
to engage in mobile research protocols
(engagement), and the cost of this research
(cost) remain untested.
Objective To assess the feasibility of a fully
mobile randomised controlled trial using
assessments and treatments delivered entirely
through mobile devices to depressed individuals.
Design Using a web-based research portal,
adult participants with depression who also
owned a smart device were screened, consented
and randomised to 1 of 3 mental health apps for
treatment. Assessments of self-reported mood
and cognitive function were conducted at
baseline, 4, 8 and 12 weeks. Physical and social
activity was monitored daily using passively
collected phone use data. All treatment and
assessment tools were housed on each
participant’s smart phone or tablet.
Interventions A cognitive training application,
an application based on problem-solving therapy,
and a mobile-sensing application promoting daily
activities.
Results Access: We screened 2923 people and
enrolled 1098 participants in 5 months. The
sample characteristics were comparable to the
2013 US census data. Recruitment via Craigslist.
org yielded the largest sample. Engagement:
Study engagement was high during the
first 2 weeks of treatment, falling to 44%
adherence by the 4th week. Cost: The total
amount spent on for this project, including
staff costs and β testing, was $314 264 over
2 years.
Conclusions and relevance These findings
suggest that mobile randomised control trials can
recruit large numbers of participants in a short
period of time and with minimal cost, but study
engagement remains challenging.
Trial registration number NCT00540865.
INTRODUCTION
Five hundred million individuals use
mental health apps worldwide, with these
numbers expected to reach 1.7 billion by
2018.1 The potential for mobile devices
to revolutionise healthcare and clinical
research has not been lost on either
industry2 3 or academia.4–6 Notable
examples of initiatives to collect behav-
ioural data using mobile technology are
the Patient-Centered Outcomes Research
Institute (PCORI)-funded Patient-
Centered Clinical Outcomes Research
Networks, National Institutes of Health
(NIH’s) Precision Medicine Initiative, and
Apple’s Research Kit. Indeed, the use
of smart technology appears to be a
clear avenue to increase research
participation.7 8
Mobile technologies may be particu-
larly useful in improving participant
access to and reducing expenses of rando-
mised clinical trials (RCTs). Typical RCTs
cost millions of dollars and recruit 200–
300 participants in 3–5 years.9 Sample
demographics are determined by the
location of the research institution, limit-
ing the representativeness of many RCT
samples. Expense and access problems
are exacerbated when trying to study
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populations who are challenging to recruit, such as
those with mental illnesses, people living in rural
areas or racial/ethnic minority populations.
One solution to overcome access and cost issues has
been the use of the internet to conduct randomised
control studies. These trials are beneficial from the
cost perspective, with estimated cost reductions of
more than 50% compared with conventional
trials,10 11 and from the access perspective, these
studies recruit very large samples in short periods of
time.12 13 However, retention issues are particularly
problematic for internet studies, with one recent
internet-based trial reporting a drop-out rate of over
90% in a sample of 3000 individuals.14 Drop-out is
likely due in part to the need to access a WiFi connec-
tion and dependence on an immobile device (eg, a
desktop computer). A potential advantage to research
using mobile devices (smart phones and tablets) is that
data can be collected anywhere at any time. These
devices also facilitate passive data collection such as
Global Positioning System (GPS) information from the
phone’s accelerometer and media usage to gauge
social and physical activity that can supplement self-
reports. However, while mobile technology may be
able to further expand the reach of clinical research,
this approach has yet to be tested.
The purpose of this study is to determine the feasi-
bility of conducting a fully remote RCT using smart
devices in depressed adults 18 years old and older. We
elected to study depression as our clinical focus given
its ubiquitous presence in mental illnesses and disabil-
ity.15 It is the leading cause of disability world-
wide,16 17 and the enrolment of depressed individuals
into clinical trials is difficult.18 19 In this paper, we
report data on population access (sample representa-
tiveness), engagement assessment and cost to complete
the study.
METHODS
Ethical approval for the trial was granted by the
UCSF Committee for Human Research.
Recruitment
To test our hypotheses about access, we used three dif-
ferent types of recruitment approaches: traditional,
social networking and search engine-based methods.
Traditional methods were written ads placed in city
buses, newspapers and Craigslist postings throughout
the USA. Social networking methods included regular
postings on sites such as Facebook and Twitter, and
contextual-targeting methods to identify and directly
push recruitment ads to potential participants, based
on their Twitter and other social media comments.
Our search engine-based method included using
Google Adwords, a historically successful recruitment
tool.20 Each approach (described further in see online
supplementary materials) provided potentially
interested participants a link to our custom study
website (http://www.brightenstudy.com).
Participant eligibility
Participants had to speak English, be 18 years old or
older, own a smartphone (iPhone or Android) with
WiFi or 3G/4G capabilities, and own an iPad2 or
newer device. iPad ownership was required as our
cognitive assessment tool was only available on this
device at the time of the study. To characterise recruit-
ing logistics without this restriction, individuals
without an iPad but with a smartphone were given the
opportunity to participate in phone-only study arms
that were not part of the randomised sample. A
Patient Health Questionnaire (PHQ-9),21 score of 5
or greater, or a score of 2 or greater on PHQ item 10
(indicating that they felt disabled in their life because
of their mood), was also required for enrolment.
Procedure
Screening
Potential participants were directed to a website
(http://www.brightenstudy.com) explaining the study
purpose and procedures. Interested participants com-
pleted an online brief screening consisting of ques-
tions about mobile device ownership.
Consent
We used a combination of a written consent and
custom videos posted on YouTube to explain the
study. Participants had to pass a quiz that tested their
understanding that the study was voluntary, was not a
substitute for treatment and that they were to be ran-
domised. Each question had to be answered correctly
before moving on to baseline assessment and random-
isation. Eligibility was established after consent was
obtained.
Randomisation
Participants were randomised to one of three treat-
ment arms where they viewed a brief video explaining
how to download and use the assessment and assigned
treatment app. Participants were also given a link to
view a custom dashboard of their study progress.
Treatment
Participants were asked to use their assigned app for
1 month. The first app was a cognitive intervention
video game (Project: EVO™, or EVO) designed to
modulate cognitive control abilities, a common neuro-
logical deficit underlying depression.22 The second
intervention was an app based on an evidence-based
treatment for depression (problem-solving therapy, or
PST).23 The final intervention app, an information
control, provided daily health tips (HT) for overcom-
ing depressed mood such as self-care (eg, taking a
shower) or physical activity (eg, taking a walk; see
online supplementary materials for further descrip-
tions of each).
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Assessment
We used two apps to collect baseline and 4, 8 and
12 weeks of outcome data. The first app, developed
by Ginger.io™ was used to collect self-reported
mood, function and passive analytics such as commu-
nication data (text logs including call/text time, call
duration, text length and screen usage), and mobility
data (activity type and distance travelled using the
phone’s accelerometer and GPS). The second app was
a mobile cognitive assessment app (Adaptive
Cognitive Evaluation (ACE)), to measure cognitive
control processes (see online supplementary etable 1).
Participants were automatically notified every 8 h for
24 h if they had not completed a survey within 8 h of
its original delivery. An assessment was considered
missing if it was not completed within this 24 h time
frame.
The baseline assessment included the collection of
demographics including age, race/ethnicity, martial
and employment status, income, education, smart
device ownership, use of other health apps, and use
of mental health services, including use of medications
and psychotherapy. We collected information on
mental health status using the PHQ-924 for depres-
sion, the generalized anxiety disorder (GAD)-7,22 for
generalised anxiety, a four-item mania and psychosis-
screening instrument25 and the four-item National
Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alcohol Screening Test.26 To assess for self-reported
disability, we used the Sheehan Disability Scale.27 28
We also asked participants to rate their health on a
scale of excellent to poor.
Daily assessments were a combination of self-
report and passive data collection. Participants com-
pleted the PHQ-2 (mood and enjoyment) every
morning. The Ginger.io app collected passive analy-
tics daily. Private information such as actual content
of voice calls or text messages or emails was not
collected.
The 4-week, 8-week and 12-week assessments
included the PHQ-9 to measure changes in mood,
ACE for changes in cognitive control, and the
Sheehan for changes in disability. Participants were
also asked this question: ‘since using this app, I feel
that I am: (1) much worse, (2) worse, (3) no different,
(4) improved, (5) much improved’.
Payment
Randomised participants were paid a total of $75
for completing all assessments over the 12 weeks via
Amazon gift vouchers, while participants in the
phone-only arms were paid $45 as they did not
complete the cognitive assessment. To test if
increased payment led to increased adherence and
retention, a subset of participants (n=144) were
given $75 in bonus pay if they completed all
assessments.
Procedures to reduce gaming
‘Gaming’ is a situation where a user fraudulently
enrols in a study solely to acquire research payment.
We utilised the following safeguards to prevent this:
(1) locking the eligibility survey if a participant tried
to change a submitted answer, (2) using study links
that are valid for one user/device, and (3) tracking IP
addresses to minimise duplicate enrolment.
Statistical analyses
To assess participant access, we describe the sample
demographics, clinical characteristics and sample
comorbidities using the appropriate descriptive statis-
tics. To assess participant engagement, we examined
the proportion of study drop-outs and the proportion
of enrolled individuals who responded to the primary
mood outcome measures at each time point using a
mixed-model analysis of variance (with
Greenhouse-Geisser corrections when needed). To cal-
culate time to drop-out, we tested a survival analysis
model with the distribution of the ‘survival’ times for
those assigned each app estimated and non-parametric
estimates of the survivor function computed by the
Kaplan-Meier method, with curves tested using the
log-rank test using Stata V.14.0. We also examined
whether there was a significant difference in drop-out
rates among the three interventions using Pearson’s χ2
test. Pairwise log-rank tests were conducted to
determine where there were significant differences
between the distributions, and a Bonferroni correc-
tion was set at p<0.017 to correct for multiple
comparisons. We also compared these outcomes for
the entire sample and by sample type (randomised
and non-randomised). To assess issues surrounding
cost, we describe a total study cost approach factor-
ing in β testing, staff time and efforts beyond those





National recruitment began in August of 2014, and
was conducted in five, 2-week advertising waves (total
of 5 months of recruitment). We recruited a total of
2923 participants. Of these recruited individuals,
1098 were enrolled to the randomised (N=626) and
non-randomised (N=472) arms of the study (see
figure 1). Eighty-nine per cent of the sample came
from traditional recruitment approaches, <1% came
from social networking, <1% came from search
engine-based methods, and 10.3% came from
unanticipated means (own search, referrals). We were
able to successfully recruit individuals from 8 of the
15 most rural states in the USA29 without any targeted
recruitment efforts (see figure 2A).
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Figure 1 CONSORT diagram (HT, health tips; PHQ, Patient Health Questionnaire).
Figure 2 Demographic characteristics. (A) Percentage of recruited participants across the USA. (B) Percentage of participants within
different age ranges from the recruited sample. (C) Ethnic composition of the recruited individuals, and its comparison to the
observed ethnic composition reported in the 2013 US Census.
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Sample demographics
Participants were primarily young adults (see figure 2B),
although age ranged from 18 to 76, with 79% identify-
ing as female. Fifty-eight per cent of our sample was
non-Hispanic white, and an ethnicity distribution com-
parable to the 2013 US Census (see figure 2C).
Fifty-seven per cent of our participants obtained a
4-year college degree or higher, with a mean annual
income of $30–$35 000 (see table 1). Sixty-seven per
cent of our participants were employed at the time of
enrolment. There was a difference in age between ran-
domised and phone-only assigned participants, with
randomised participants slightly older than phone-only
participants, t(954.38)=−3.22, p=0.001. However,
there was no difference in gender between these groups
(x21=0.08, p=0.77). Enrolled individuals who were
single/never married reported greater symptoms of
depression (t[528.17]=2.96, p=0.003).
Clinical characteristics
The sample was moderately depressed at baseline,
with a PHQ-9 mean score of 13.9 (SD=5.1). There
was a significant association between age and depres-
sion severity, Spearman’s r=−0.11, p<0.001. There
was no significant difference in depression severity
among gender (t(365.85)=0.63, p=0.53) or ethnic
groups, (F(6, 1091)=1.37, p=0.22). Fifty-one per
cent reported comorbid anxiety, 53% reported
comorbid alcohol misuse, 16% reported a history of
psychosis or mania. In total, 54.5% of our sample was
receiving mental health treatment for their depression.
This sample mirrored the ethnic disparities in mental
health service use found in the general population,
with 63% of non-Hispanic white participants in treat-
ment, and only 42% of ethnic minorities were in
treatment (x21=28.6, p<0.001, OR=2.29). There
were no significant differences in depression severity
among individuals randomised to the three primary
arms (F[2, 623]=0.14, p=0.87; see table 1).
Engagement
Sixty-six per cent of the sample completed the 4-week
assessment, 50% completed the 8-week assessment
and 41% completed the 12-week assessment (see
figure 3A). There was no adherence difference by
group (F(2, 241)=2.50, p=0.08) and no time by
group interaction (F(3.55, 428.14)=1.93, p=0.11).
Table 1 Baseline demographics
Variable PST EVO (iPad) HT (iPad) EVO (iPhone) HT (Android)
Age 34.91 (12.33) 33.37 (10.87) 33.56 (12.27) 30.33 (11.11) 32.41 (10.26)
Education
<12 years 39 (18.48) 31 (14.83) 36 (17.48) 52 (21.85) 77 (32.91)
College 133 (63.03) 129 (61.72) 122 (59.22) 148 (62.18) 125 (53.42)
Graduate 39 (18.48) 49 (23.44) 49 (23.30) 38 (15.97) 32 (13.68)
Income+
$20 000 or less 42 (35.00) 31 (35.23) 39 (31.71) 73 (53.28) 79 (58.96)
$20 000–$40 000 32 (26.67) 21 (23.86) 30 (24.39) 37 (27.01) 34 (25.37)
$40 000–$60 000 26 (21.67) 17 (19.32) 17 (13.82) 18 (13.14) 14 (10.45)
$60 000–$80 000 6 (5.00) 9 (10.23) 18 (14.63) 7 (5.11) 4 (2.99)
$80 000–$100 000 6 (5.00) 3 (3.41) 7 (5.69) 1 (0.73) 1 (0.75)
$100 000+ 8 (6.67) 7 (7.95) 12 (9.76) 1 (0.73) 2 (1.49)
Number of females 160 (75.83) 161 (77.03) 173 (83.98) 198 (83.19) 172 (73.50)
Per cent of minority 83 (39.34) 87 (41.63) 82 (39.81) 94 (39.50) 110 (47.01)
Marital status
Single 118 (55.92) 112 (53.59) 118 (57.28) 164 (68.91) 150 (64.10)
Married 62 (29.38) 73 (34.93) 68 (33.01) 53 (22.27) 53 (22.65)
Divorced/separated/widowed 31 (14.69) 24 (11.48) 20 (9.71) 21 (8.82) 31 (13.25)
Psychiatric
PHQ-9 13.76 (4.91) 13.51 (5.06) 13.64 (4.90) 13.61 (5.02) 15.01 (5.23)
GAD 10.36 (4.97) 9.15 (4.92) 10.39 (5.32) 10.54 (5.53) 10.38 (5.46)
NIAAA 3.20 (2.54) 3.03 (2.24) 3.40 (2.31) 3.34 (2.35) 2.98 (2.43)
Mania Hx 22 (14.57) 15 (11.90) 20 (14.71) 25 (16.03) 25 (15.15)
Psychosis Hx 2 (1.32) 1 (0.79) 3 (2.21) 3 (1.92) 3 (1.82)
Using other health apps 128 (87.67) 105 (84) 116 (86.57) 124 (79.49) 125 (77.64)
Per cent of rural 5 (2.37) 3 (1.44) 7 (3.40) 9 (3.78) 5 (2.14)
In treatment 84 (57.5) 64 (52.5) 74 (56.5) 84 (55.3) 81 (50.9)
Mean (SD) for continuous variables; number (percentage) for categorical.
HT, health tips; Hx, medical history; PHQ, Patient Health Questionnaire; PST, problem solving therapy.
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We found similar adherence to the cognitive assess-
ment tool, with neither a group (F=0.46, p=0.63)
nor interaction effect present (F=0.91, p=0.42).
Although lower assessment adherence was observed in
the more depressed participants, younger participants,
and participants with lower education, the effects
sizes were small (see table 2).
Kaplan-Meier survival analysis was conducted to
determine whether intervention assignment or any
baseline demographic variables predicted drop-out
status. The log-rank test revealed a significant differ-
ence between the survival distributions between
groups (x22=19.27, p<0.001), with the EVO arm
having significantly earlier time to drop-out than the
PST arm (x21=7.45, p=0.01) or HT (x
2
1=17.51,
p<0.001) arms (see figure 3B). We did not find a sig-
nificant difference in survival distributions for those
with high versus low PHQ-9 scores (using a PHQ-9
score of 10 as a cut-point, x22=2.29, p=0.13). There
was no significant difference in survival distributions
between non-Hispanic whites and ethnic minorities
(x21=2.13, p=0.14). Participants who received bonus
pay remained in the study longer than those who did
not receive a bonus (x21=11.82, p<0.001). Bonus pay
was for assessment completion, not intervention app
use.
Cost
Total study costs included participant payments
($23 320), website/enrolment portal/database develop-
ment ($46 507), and salaried staff time (3; 2 student
volunteers also assisted) over the 9 months the study
was active ($58 917), summing to a total of $128 444.
The total amount spent on for this project, including
staff costs, development and β testing of the UCSF
developed apps (ACE and iPST), and licensing fees for
Figure 3 Intervention and assessment adherence. (A)
Percentage of individuals who responded to their mood
assessment during the treatment phase (first 4 weeks) and
follow-up periods (weeks 8 and 12). (B) Kaplan-Meier survival
estimates per study arm illustrating survival distributions of time
to drop-out (last day of recorded activity) over the course of the
study (84 days).
Table 2 Baseline demographics*
Assessment adherence Adherent Non-adherent p Value Effect size†
PHQ-9‡ 13.25 (5.0) 14.5 (4.9) 0.001 0.24
Age‡ 34.7 (11.4) 30.7 (10.8) <0.001 0.36
Education§ <0.01 0.25
<12 years 61 (17.09) 95 (25.54)
College 206 (57.70) 211 (56.72)
Graduate 90 (25.21) 66 (17.74)
Gender¶ 80 (22.4) 75 (20.2) 0.46 0.11
Minority** 130 (36.4) 161 (43.3) 0.06 0.23
Income†† 0.06 0.33
$20 000 or less 81 (39.32) 91 (47.40)
$20 000–$40 000 50 (24.27) 52 (27.08)
$40 000–$60 000 34 (16.50) 30 (15.62)
$60 000–$80 000 21 (10.19) 7 (3.65)
$80 000–$100 000 6 (2.91) 6 (3.12)
$100 000+ 14 (6.80) 6 (3.12)
*Means and SDs unless otherwise specified.
†All effect sizes converted to Cohen’s d.
‡Welch t test.
§Pearson χ2 test; number and percentage.
¶Pearson χ2 test; number and percentage of males.
**Pearson χ2 test; number and percentage of ethnic minorities.
††Fisher’s exact test; number and percentage.
PHQ, Patient Health Questionnaire.
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the use of the other apps (EVO and Ginger.io) was
$314 264 over 2 years.
DISCUSSION
The results from this study have a number of important
implications for the future of RCTs in mental health.
First, we recruited a large sample of depressed partici-
pants in a short period of time and with minimal cost
and effort. Currently, the typical RCT takes 4–5 years
to complete, and another 1–2 years before the out-
comes from these trials are reported publically. Rapid
recruitment has the potential for quickly testing inter-
vention efficacy and effectiveness, and ultimately
moving effective treatments into practice while identi-
fying and preventing the proliferation of ineffective,
even unsafe, treatments. Second, we were able to
recruit a highly representative sample of the US popu-
lation, without any specific cultural adaptations or tar-
geted advertising. Remote research methods could
address decades-long concerns about the generalisabil-
ity of clinical findings to minority samples not typically
represented in clinical research. Finally, the cost of a
fully remote RCT could allow for greater distribution
of dwindling clinical research and development funds
from federal, foundation and industry sponsors.
Investment in large-scale clinical trials is a costly
endeavour, resulting in the need to focus funds on only
a few research areas. Although not all mental health
RCTs should be fully remote, particularly those that
test hypotheses about biological or neurological pro-
cesses that can only be measured with immobile
devices, the methods presented here, such as auto-
mated data collection of neuropsychological processes
could result in substantial savings, which in turn could
be invested in a diverse research portfolio.
This research method is not without its limitations.
Primary among the challenges of fully remote research
is the ability to keep participants engaged in the study
protocol over time. Although there is an appeal to
quickly recruiting and retaining large numbers of par-
ticipants in an RCT, researchers and developers need
to be cautious when interpreting outcomes from
samples with a drop-out rate greater than 70%.30–33
However, it is important to point out here that the
project was completely automated with very little
contact between the participant and research team,
and our retention rates were higher than in the typical
internet-based RCT.34 Internet-based studies have
shown that when there is more direct contact between
the research team and participant through technolo-
gies such as video-over-internet protocols, retention
rates are greater and less subject to bias,35 suggesting a
hybrid approach may provide an optimal response.
Although we experimented with two incentive
models to encourage retention, we determined that
participant payment was not enough to keep engage-
ment from waning across the course of the study, as
bonus pay only encouraged participants to complete
their assessments, and did not engender any additional
motivation to utilise the training apps. Previous work
has demonstrated that externalised benefits in the
form of compensation can dull motivation,36 37 indi-
cating that the creation of internalised reward struc-
ture to enhance motivation (eg, individualised
presentation of study progress, personalised encour-
agements) is critical for improved adherence.
CONCLUSIONS
Mobile technology has an important role in broaden-
ing the reach and representativeness of RCTs, while
substantially reducing the time to determine interven-
tion effectiveness and reducing study costs. Although
study retention remains challenging for technology-
based research, innovative methods to increase motiv-
ation and study engagement could easily address this
important limitation.
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